Relay Therapeutics, Inc.
RLAY
Classement en actions
#4288
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Prix de l'action
$16.90
Capitalisation boursière
$3.70B
Changement (1 jour)
3.81%
Changement (1 an)
160.40%
Pays
US
Échange Relay Therapeutics, Inc. (RLAY)
Catégorie
Healthcare
EPS pour Relay Therapeutics, Inc. (RLAY)
EPS au June 2026 TTM : $-1.57
Selon les derniers rapports financiers et le cours de l'action de Relay Therapeutics, Inc., l’EPS actuel de la société (TTM) est de $-1.57. À la fin de 2023, la société avait un EPS de $-2.79 une augmentation par rapport à celui de 2022, qui était de $-2.59.
Historique de l'EPS de Relay Therapeutics, Inc. de 2018 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-1.57 | -33.47% |
| 2024 | $-2.36 | -15.41% |
| 2023 | $-2.79 | 7.72% |
| 2022 | $-2.59 | -32.20% |
| 2021 | $-3.82 | 49.22% |
| 2020 | $-2.56 | -83.52% |
| 2019 | $-15.53 | -20.89% |
| 2018 | $-19.63 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -1,203.18% |
US
|
|
| $-7.98 | 408.28% |
US
|
|
| $-5.29 | 236.94% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,866.88% |
NL
|
